Clinical Trial Update: A Phase II Study of AZD4877 (a Novel Anti-mitotic Agent) in Advanced Bladder Cancer [Phase 2]

View source ↗

Summary

This document reports the completion and results posting of a Phase II study of AZD4877, an anti-mitotic agent, in advanced bladder cancer and related urothelia…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer
• Urothelial Carcinoma of the Bladder
• Urothelial Carcinoma of the Renal Pelvis
• Urothelial Carcinoma of the Ureter
• Urothelial Carcinoma of the Urethra

Drugs mentioned

• AZD4877

Snippet

Sponsor: AstraZeneca | Conditions: Bladder Cancer, Transitional Cell Bladder Cancer | Phase 2 | Status: COMPLETED | Results posted: 2011-01-12